Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Completed · Phase 3 · NCT02414854
Conditions: Asthma
At a glance
- Research payments reported, 2025
- $17,000
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 1,902
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Placebo (drug), Inhaled corticosteroid (ICS) therapy (drug), Albuterol/Salbutamol (drug), Levalbuterol/Levosalbutamol (drug)
- Dates
- Started 2015-04-27; completion 2017-11-23
- Results posted
- Yes
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life. * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
From ClinicalTrials.gov, last updated 2018-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $17,000 in research payments for this study in 2025 (38 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $17,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.